Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification
NCT ID: NCT06674772
Last Updated: 2024-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
440 participants
OBSERVATIONAL
2022-11-29
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)
NCT00687947
Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine
NCT00772473
Plasma Levels of CGRP and Expression of Specific microRNAs in Blood Cells of Episodic and Chronic Migraine Subjects
NCT04473976
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies
NCT04503083
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A sample of saliva will be collected in order to measure CGRP levels and a blood sample will be collected in order to conduct a DNA test and hormones test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Migraine Patients
Patients, male and female, with Episodic migraine, all ages.
Saliva test
Sampling of CGRP in saliva and DNA blood test and sex hormones blood test.
Control group
Male and female without migraine or headache
Saliva test
Sampling of CGRP in saliva and DNA blood test and sex hormones blood test.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saliva test
Sampling of CGRP in saliva and DNA blood test and sex hormones blood test.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy controls paired to patient age and sex, without headache and without first degree family history of headache.
Exclusion Criteria
* Presence of any salivary gland malfunction.
* Abuse or dependence to tobacco, alcohol or any drug in the previous 12 months before the enrollment.
* Active migraine preventive treatment.
* Pregnant or breastfeeding female.
6 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitari Vall d'Hebron Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vall d'Hebron University Hospital
Barcelona, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PR(AG)350/2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.